Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vamorolone - Santhera Pharmaceuticals

Next Previous
X
Search
Drug Profile

Vamorolone - Santhera Pharmaceuticals

Alternative Names: AGAMREE; VB-15; VBP-15

Latest Information Update: 06 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ReveraGen BioPharma
  • Developer ReveraGen BioPharma; Santhera Pharmaceuticals; Sperogenix Therapeutics
  • Class Anti-inflammatories; Antianaemics; Antiasthmatics; Antifibrotics; Antineoplastics; Antirheumatics; Corticosteroids; Glucocorticoids; Pregnatrienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Duchenne muscular dystrophy
  • Preclinical Unspecified
  • Discontinued Amyotrophic lateral sclerosis; Asthma; Brain cancer; Cystic fibrosis; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Sickle cell anaemia; Spinal muscular atrophy

Most Recent Events

  • 06 May 2024 Santhera Pharmaceuticals initiates a early access programme for Duchenne muscular dystrophy in France
  • 25 Apr 2024 Santhera Pharmaceuticals anticipates approval of vamorolone for Duchenne muscular dystrophy in China in Q1 2025
  • 25 Apr 2024 Santhera Pharmaceuticals announces intention to launch vamorolone for the treatment of Duchenne muscular dystrophy (In children, In adolescents, In adults, In the elderly) in the United Kingdom in 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top